PhRMA Starts New Year With Familiar Drug Pricing Proposals Targeting The Supply Chain

 
• By Cathy Kelly
  
USPills
Rebate Reform, 340B Oversight On PhRMA's Agenda For 2020

More from Pricing Debate

More from Market Access